Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer

Review summary

A phase II trial combining the PARP inhibitor olaparib with the checkpoint inhibitor durvalumab in metastatic castration-resistant prostate cancer — a DDR + immunotherapy combination paralleling our POLAR strategy.